Crizotinib - Wikiwand
Molecular mechanisms of crizotinib in ROS1-rearranged lung cancer patients. | Download Scientific Diagram
Cancer Research and Treatment
Alectinib Hydrochloride
Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor | Personalized Medicine in Oncology
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death | Haematologica
Frontiers | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC | Oncology
Agents Targeting ROS1 Gain Traction in NSCLC
Molecular mechanisms of crizotinib resistance in ROS1, depicting the... | Download Scientific Diagram
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance | Oncotarget
Frontiers | ALK Inhibitors, a Pharmaceutical Perspective | Oncology
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, develop | DDDT
Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer - Poon - 2017 - International Journal of Cancer - Wiley Online Library
Therapeutic management of ALK+ nonsmall cell lung cancer patients | European Respiratory Society
Crizotinib (Xalkori) - Oncology Nurse Advisor
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET - Lung Cancer
Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer - Poon - 2017 - International Journal of Cancer - Wiley Online Library
Crizotinib resistance: implications for therapeutic strategies - Annals of Oncology
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Abstract - Europe PMC
Mechanisms of resistance to crizotinib. | Download Scientific Diagram
eML4–ALK pathways and the mechanism of resistance to crizotinib. Notes:... | Download Scientific Diagram
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET - Journal of Biological Chemistry
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer - ScienceDirect
Frontiers | A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer | Oncology
